SureTrader Nadex Advertisement PGUS
Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, kkpennies, Peter Lynch, NewTrader2017
Search This Board: 
Last Post: 3/23/2017 2:22:37 PM - Followers: 119 - Board type: Free - Posts Today: 20


Company will release its fourth quarter and full year 2016 financial results and provide a corporate update on Monday, March 6, 2017, after the close of the U.S. financial markets. The Company will host a conference call at 4:30 p.m. ET/1:30 p.m. PT on the same day to discuss the financial results and recent business developments.

To participate in the call, please dial 1-877-883-0383 for domestic callers or 1-412-902-6506 for international callers. Participant Elite Entry Number: 5095822. A replay of the call will be available for 30 days. To access the replay, dial 1-877-344-7529 domestically or 1-412-317-0088 internationally and reference Conference ID: 10102614. The replay will be available shortly after the end of the conference call.
* shareholders, please consider purchasing product(s)


Awaiting Official Announcement of FDA Approval for FlutiCare

FlutiCare Approval could bring a BILLION DOLLARS in sales annually

REDONDO BEACH, CA--(Marketwired - Jul 12, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, discusses the potential impact of the anticipated FDA ruling on Innovus Pharmaceuticals' (OTCQB: INNV) ANDA filing for FlutiCare™, the company's over-the-counter treatment for allergic rhinitis.

FlutiCare™ is designed to treat non-allergic rhinitis -- better known as "hay fever" or "stuffy nose" -- which affects roughly 50 million Americans each year. While 70% of these individuals use over-the-counter products, more than half are not satisfied with the treatment option, according to an Asthma and Allergy Foundation of America survey, which suggests there's an opportunity for a prescription-strength OTC treatment option to capture market share from category leaders.

As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. The FDA decision is expected in the next several weeks.


The CEO has already signed an agreement for the manufacturing of FlutiCare

Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision

SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles.  Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.


Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. 
where he helped move the company's stock price from
19 Cents to $6.00 !!!
(Uplisted from OTC to NASDAQ)


Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.
President and Chief Executive Officer:

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.


Robert E. Hoffman
Executive Vice President and Chief Financial Officer:

Mr. Hoffman was appointed as our Executive Vice President and Chief Financial Officer on September 6, 2016. Prior to Innovus Pharma, Mr. Hoffman was Chief Financial Officer of AnaptysBio, Inc., a clinical stage biopharmaceutical company. He was part of the founding management team of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), a biopharmaceutical company, in 1997, serving as Senior Vice President, Finance and Chief Financial Officer until 2015. He also served as Chief Financial Officer for Polaris Group, a biopharmaceutical drug company, from March 2011 to August 2011. Mr. Hoffman is a member of the board of directors of CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company, Kura Oncology, Inc. (NASDAQ:KURA), a biotechnology company, and MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX), a biopharmaceutical company. He also was a member of the Financial Accounting Standards Board’s Small Business Advisory Committee until 2015 and is a member of the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman received his B.B.A. from St. Bonaventure University, and is licensed as a C.P.A. (inactive) in the State of California.


Who are the major players at Innovus Pharma?


Share Structure:

Shares Outstanding:     124.8 Million (as of 3/3/17)   Dr. Damaj owns $23+M shares alone

- Current cash on-hand is enough to fund operations through Q3 of 2017.  Profitability expected exiting Q4 2017 !
- 2017 Projected Revenue of $15M (NOT counting FlutiCare), which would be approximately 3x GREATER than 2016. 


Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call

Corporate Presentation November 2016 (8-K  11/1/2016)

Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)

Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products

Major 2016 Accomplishments:



Where can INNV products be seen?


Existing Product Lines @ Innovus Pharma:

Are you looking to boost your brain health?r

** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
INNV News: Current Report Filing (8-k) 03/22/2017 06:06:54 AM
INNV News: Prospectus Filed Pursuant to Rule 424(b)(4) (424b4) 03/20/2017 06:10:07 AM
INNV News: Prospectus Filed Pursuant to Rule 424(b)(1) (424b1) 03/17/2017 03:57:15 PM
INNV News: Notice of Effectiveness (effect) 03/16/2017 06:02:44 AM
INNV News: Securities Registration Statement (s-1/a) 03/15/2017 06:09:33 AM
#6430  Sticky Note Innovus Pharma Announces Receipt of Notification to Commercialize kkpennies 03/08/17 04:20:02 PM
#4406  Sticky Note Proven revenue & cash positive potential for 2017. BooDog 11/17/16 06:00:40 AM
#7030   can understand the apprehension and im down a marpolo 03/23/17 02:22:37 PM
#7029   $INNV In this report, “Innovus Pharmaceuticals,” “Innovus Pharma,” The Cardiac Kid 03/23/17 02:08:36 PM
#7028   Hey marpolo, I like your take on this gi197845 03/23/17 01:36:15 PM
#7027   Although most of the "talk" has been cautious marpolo 03/23/17 01:25:17 PM
#7026   I am glad that INNV is advertising, but gi197845 03/23/17 12:59:49 PM
#7025   Read a post of his from 2 days Batermere 03/23/17 12:59:42 PM
#7024   What happened to Honey? COACH14 03/23/17 12:06:28 PM
#7023   What has adrock stated that is proven false? Bill_gates383 03/23/17 12:01:50 PM
#7022   AMEN COACH14 03/23/17 11:08:08 AM
#7020   My contact stated that the convertibles have not Adrock 03/23/17 09:12:32 AM
#7019   I hope your right. ShawnP123 03/23/17 07:49:38 AM
#7018   It is all about risk Vs. Reward from BooDog 03/23/17 07:48:11 AM
#7017   I think you will know quite a bit ShawnP123 03/23/17 07:40:04 AM
#7016   I'm looking into Q3 to Q4 report. BooDog 03/23/17 06:42:09 AM
#7015   My response is to wait until the Q2 ShawnP123 03/23/17 03:30:40 AM
#7014   Well, I think this is now my second capt_dave 03/23/17 02:02:11 AM
#7013   Shawn is a good guy. I think he mongoosevsgt 03/23/17 12:48:32 AM
#7012   Be sober-minded; be watchful. Your adversary the devil mongoosevsgt 03/23/17 12:24:03 AM
#7011   Actually it's pretty smart, sure rural areas may CT_StockMouse 03/23/17 12:23:02 AM
#7010   I reached out to IR again and asked s_Henderson 03/22/17 11:49:48 PM
#7009   30% gap bucko TrueTrades 03/22/17 11:26:17 PM
#7008   no the market will kill this one TrueTrades 03/22/17 11:23:38 PM
#7007   Only DDS losers use amalgam anymore, Bucko. This Batermere 03/22/17 11:19:32 PM
#7006   peter will sell paul a lot of products mongoosevsgt 03/22/17 11:18:45 PM
#7005   gonna take a lot of amalgamated filling to TrueTrades 03/22/17 11:14:37 PM
#7004   I hear you, yo. I hope dey now mongoosevsgt 03/22/17 11:13:20 PM
#7003   This is hilarious entertainment tonight. So Adrock claims Batermere 03/22/17 10:18:37 PM
#7002   Fear monger. My money is on Damaj and sweetstreet 03/22/17 10:05:48 PM
#7001   What a wild week huh? Power_C 03/22/17 09:31:17 PM
#7000   Nice Try , but nobody listen to you healthywelth 03/22/17 08:55:18 PM
#6999   Saw a half page add in my local codaras 03/22/17 08:36:21 PM
#6998   Let's start by "reviewing" your SP prediction of Batermere 03/22/17 08:31:23 PM
#6997   So let's review today, they announce they supposedly Adrock 03/22/17 08:18:44 PM
#6996   and mary of magdalene ? mongoosevsgt 03/22/17 06:41:21 PM
#6995   Probably works at those gift shops or Subways mongoosevsgt 03/22/17 06:38:58 PM
#6994   robbing peter to pay paul TrueTrades 03/22/17 06:37:36 PM
#6993   Perfect. Eom BooDog 03/22/17 06:24:39 PM
#6992   No, they are certainly not "investors". This is Batermere 03/22/17 05:35:20 PM
#6991   Even worse, the PPS of OTC stocks like s_Henderson 03/22/17 05:26:58 PM
#6990   Thanks Shawn. Looking forward for follow through here. BooDog 03/22/17 05:12:16 PM
#6989   True dat, jb. This MB has more morons Batermere 03/22/17 04:59:23 PM
#6988   Darwin should have added another law of nature.."Stupid jbdiver 03/22/17 04:49:21 PM
#6987   BooDog- There's a difference between qualification for a ShawnP123 03/22/17 04:48:14 PM
#6986   Sure you do, TRUMP. Just like your best Batermere 03/22/17 04:41:41 PM
#6985   That's quite the assumption there bud. I have GTTTR15 03/22/17 04:02:32 PM
#6984   I think i own the most share than TRUMPFORPRES 03/22/17 03:52:44 PM
#6983   BTW were losing all green footing today! smh jbdiver 03/22/17 03:13:16 PM
#6982   Might have been something worth mentioning in the jbdiver 03/22/17 03:10:56 PM
#6981   Thankfully we're already years in so chances improve BooDog 03/22/17 03:10:49 PM
#6980   This might be interesting info for fellow investors. s_Henderson 03/22/17 02:59:15 PM